Sage Mountain Advisors LLC Has $107,000 Holdings in Haleon plc (NYSE:HLN)

Sage Mountain Advisors LLC lessened its stake in Haleon plc (NYSE:HLN) by 30.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 11,236 shares of the company’s stock after selling 4,902 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Haleon were worth $107,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Sierra Ocean LLC acquired a new position in Haleon during the fourth quarter worth $26,000. Versant Capital Management Inc boosted its holdings in Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Haleon during the fourth quarter worth $35,000. Toronto Dominion Bank raised its position in Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after acquiring an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management bought a new stake in Haleon during the fourth quarter worth $39,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Hsbc Global Res lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Finally, HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Haleon has an average rating of “Hold” and an average target price of $10.95.

Haleon Price Performance

Shares of HLN opened at $10.20 on Thursday. The firm has a market capitalization of $46.15 billion, a PE ratio of 29.99, a PEG ratio of 2.82 and a beta of 0.25. The company’s 50-day moving average is $9.71 and its 200-day moving average is $9.87. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Equities analysts forecast that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. This represents a yield of 1.6%. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.